Current CFO of ImmunoPrecise Antibodies Brad McConn Resigns

ImmunoPrecise Antibodies (IPA) (NASDAQ: IPA) has officially announced the resignation of Brad McConn from his position as Chief Financial Officer, effective September 29, 2023. In response, IPA has appointed Kristin Taylor, MBA, CPA, as the interim Chief Financial Officer.

Dr. James Kuo, Chairman of the Board, expressed his appreciation for Brad’s leadership and contributions while extending best wishes for his future endeavors. Dr. Kuo also welcomed Kristin Taylor as the interim CFO. He emphasized Ms. Taylor’s extensive executive management experience, particularly in the life sciences sector, along with her strong background in capital markets and investor relations. Dr. Kuo expressed confidence in the combined capabilities of Kristin Taylor and IPA’s existing accounting, financial reporting, and treasury teams to ensure a seamless transition in all CFO-related responsibilities.

ImmunoPrecise Antibodies Ltd. operates through various subsidiaries in North America and Europe, including entities like Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd., and ImmunoPrecise Antibodies (Europe) B.V. Collectively known as the “IPA Family,” these subsidiaries form a biotherapeutic research and technology group specializing in systems biology, multi-omics modeling, and complex artificial intelligence systems.

Have you read?
The World’s Top 10 Highest-Paid Wealth Management Executives.
CEO compensation: Highest paid chief executive officers in the United States in 2022.
Highly-Paid Entertainment Chief Executives (Averaged $31.66 Million), 2022.
Highest paid health insurance CEOs.
Most Powerful Companies in Australia, 2023.